Although oseltamivir drug, it is recommended and commonly
used for the treatment of pregnant females Although some studies
suggest that oseltamivir carboxylate area under the
plasma concentration time curve was significantly lower
and the clearance significantly higher during pregnancy
[46], most studies have not suggested a need for adjustment
of antiviral doses for pregnant women Further, transplacental transfer of the metabolite has
been demonstrated to be low and accumulation minimal
in an ex vivo human placental model [48]. Likewise, the
incidence of adverse maternal or fetal outcomes after
exposure to oseltamivir has generally not been higher
than background rates Additionally, studies
clearly documented that early antiviral therapy was
associated with overall improvement in mother and fetal
outcomes compared to late or deferred therapy A
prospective safety system is now in place to evaluate the
gestational safety of seasonal and pandemic influenza
vaccine and influenza antivirals and should provide more
useful information in the coming years